We surmise one of two possibilities. The first is that a simple arithmetic mistake occurred and was not picked up, despite otherwise meticulous attention to detail. A trickster decimal point may be to blame, and a demoted effect size of 0.29 may gain in honesty what it loses in the sex appeal of an inflated 2.9 status. A smaller effect size seems more plausible, and not only because a meta-analysis of 33 trials of selective serotonin reuptake inhibitors (SSRIs) for the treatment of adult depression (2) arrived at a pooled effect size of 0.4 but because the current study, although statistically significant, was not that clinically impressive. Only 36% of the patients treated with citalopram responded, compared to 24% of those with placebo (for a lukewarm number needed to treat of 8). These results, while modest, are respectable in their own right and nothing to sneeze at in a clinical area that has been short on proven therapeutic options. But a majestic sequoia of 2.9 they are not.